Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Stock Chart & Stats
$4.51
-$0.25(-3.72%)
At close: 4:00 PM EST
$4.51
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$1.97 - $7.78
Previous CloseN/A
Volume50.54K
Average Volume (3M)101.05K
Market Cap
$224.36M
Enterprise Value$131.18M
Total Cash (Recent Filing)$102.19M
Total Debt (Recent Filing)$182.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Mar 18, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding47,233,948
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.79
Price to Sales (P/S)2.45
P/FCF Ratio-1.56
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue5.28
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$75.00Price Target Upside1562.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Divesiran Clinical DataDurable hematocrit control and flexible, less-frequent dosing observed in early trials position divesiran as a potential disease-modifying, low-burden alternative to chronic phlebotomy or cytoreductive therapy in polycythemia vera, which could drive clinical adoption if confirmed in later studies.
RNAi Platform And Pipeline ExpansionAdvancement of extra-hepatic delivery research, updates from the AstraZeneca-partnered program, and progress across multiple RNAi assets, combined with a solid cash runway, could broaden addressable markets and support sustained long-term value creation.
Zerlasiran Partnership PotentialA strategic partnership for zerlasiran would validate commercial interest in the lipoprotein(a) program, share development risk, and could unlock meaningful valuation upside ahead of upcoming cardiovascular outcomes readouts.
Bears Say
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $1.97 and its highest was $7.78 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $224.36M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 35 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.187 by $0.037.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,233,948 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.187. Following the earnings report the stock price went up 3.365%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.00 (1562.97% Upside)
$75.00 (1562.97% Upside)
Hedge Fund Trend
Decreased
By 19.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.71%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
SLN Stock 12 Month Forecast
Average Price Target
$75.00
▲(1562.97% Upside)
Technical Analysis
Ownership Overview
28.25%
Insiders
0.10% Mutual Funds
35.01% Other Institutional Investors
36.39% Public Companies and
Individual Investors